NASDAQ$SYRE
Spyre Therapeutics Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Aeglea BioTherapeutics reported financial results for the third quarter ended September 30, 2022 and provided program updates.
Aeglea BioTherapeutics reported $75.2 million in cash as of September 30, 2022. The company recognized development fee revenues of $0.2 million in the third quarter of 2022. Research and development expenses totaled $12.0 million and general and administrative expenses totaled $7.0 million for the third quarter of 2022. Net loss totaled $18.2 million for the third quarter of 2022.
- Prioritized pegtarviliase program to optimize resources and maximize success.
- Ongoing enrollment of cohort 3 in Phase 1/2 trial of pegtarviliase for Classical Homocystinuria.
- Marketing Authorization Application for pegzilarginase for Arginase 1 Deficiency submitted by Immedica is under review by the EMA.
- Corporate restructuring announced to prioritize resources and focus on the pegtarviliase program while reducing expenses.
Headline financials
Revenue & EPS history
Spyre · Revenue · Quarterly
$174K
Forward guidance
Aeglea expects its cash, cash equivalents and marketable securities will enable it to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
-0.4%
Avg return
Earnings day
+1.3%
Avg return
5 days after
+2.3%
Avg return
30 days after
44%
17 / 39 earnings
Positive
+14.6%
Q4 2023
Best reaction
-10.9%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.6% | +7.6% | +3.6% | |
| Q3 2025 | +0.5% | +4.6% | +49.4% | |
| Q1 2025 | -2.0% | -0.7% | +13.2% | |
| Q4 2024 | +7.2% | +6.0% | -2.3% | |
| Q3 2024 | +5.6% | -4.4% | -27.7% | |
| Q2 2024 | -3.0% | -6.6% | +7.4% | |
| Q1 2024 | +11.8% | +19.0% | +2.0% | |
| Q4 2023 | +14.6% | +44.3% | +45.3% | |
| Q3 2023 | -2.2% | +10.8% | +102.2% | |
| Q2 2023 | -10.3% | -12.0% | +6.7% | |
| Q1 2023 | -6.6% | -9.1% | -18.3% | |
| Q4 2022 | -0.3% | +2.0% | -26.6% | |
| Q3 2022 | -9.0% | +3.7% | -59.0% | |
| Q2 2022 | +7.7% | +5.9% | +33.3% | |
| Q1 2022 | -10.9% | -5.8% | -60.0% | |
| Q4 2021 | +0.4% | -14.6% | +14.2% | |
| Q3 2021 | -5.4% | -5.8% | -22.5% | |
| Q2 2021 | -0.6% | -3.3% | +12.1% | |
| Q1 2021 | +2.2% | +4.4% | -8.1% | |
| Q4 2020 | +1.7% | +9.7% | +5.3% | |
| Q3 2020 | +4.5% | +22.1% | +3.5% | |
| Q2 2020 | -6.7% | -4.7% | +3.2% | |
| Q1 2020 | +10.6% | -4.5% | +24.0% | |
| Q4 2019 | -8.3% | -13.2% | -40.2% | |
| Q3 2019 | -4.3% | -2.2% | -4.1% | |
| Q2 2019 | -4.1% | -3.8% | -0.5% | |
| Q1 2019 | -1.9% | -2.1% | -8.7% | |
| Q4 2018 | -0.7% | +3.1% | +8.8% | |
| Q3 2018 | +0.2% | -13.0% | -13.3% | |
| Q2 2018 | +4.8% | +1.2% | -3.4% | |
| Q1 2018 | +3.5% | +0.6% | +4.0% | |
| Q4 2017 | -1.4% | +23.7% | +20.5% | |
| Q3 2017 | -4.9% | +4.5% | +0.0% | |
| Q2 2017 | -6.3% | -7.2% | +34.8% | |
| Q1 2017 | -2.2% | -2.0% | -43.4% | |
| Q4 2016 | -4.4% | -6.9% | -8.7% | |
| Q3 2016 | -1.2% | +1.3% | -7.5% | |
| Q2 2016 | +1.1% | -1.9% | +48.2% | |
| Q1 2016 | +0.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro